Biocytogen Pharmaceuticals Beijing (SHA:688796, HKG:2315) posted first-half attributable net profit of 241.1 million yuan, up 402% from 48.0 million yuan the previous year.
Earnings per share rose to 0.54 yuan from 0.12 yuan, according to a filing with the Shanghai bourse.
Operating revenue climbed 52% year over year to 941.4 million yuan from 621.0 million yuan.
Shares of the pharmaceutical company fell 3% in recent trade on the Shanghai bourse and rose 2% in Hong Kong.